Abbott Laboratories (ABT) Dividend Yield & History

ABT$104.71-2.74 -2.55%
Medical - DevicesLarge Cap
Compare
Market cap$181.35BEnterprise value$226.98BRevenue (TTM)$48.23BMarket positionTop 25%

Score

45
Neutral
Value
44
Quality
52
Growth
39
$104.71Price
$181.35BMarket cap
38.68P/E
18.00Forward P/E
2.41%Dividend yield

Yield is based on dividends paid in the past 12 months. 2026 isn't counted in streaks until the year ends.

At $104.71, Abbott Laboratories yields 2.41% on a past-year dividend of $2.52 a share.

Abbott Laboratories raised its yearly dividend every year from 2013 to 2025.

Abbott Laboratories last raised its quarterly dividend on 15 January 2026, from $0.59 to $0.63, up 6.8%.

Abbott Laboratories paid out 92% of its earnings over the past year as dividends and kept the rest.

Abbott Laboratories pays quarterly.

The next ex-dividend date for Abbott Laboratories hasn't been announced yet.

Five-year dividend growth at Abbott Laboratories was 10.4% a year.

Our records cover 176 payments from 1983 to 2026.

At today's yield, $10,000 invested would receive about $241 a year in dividends before tax, if payments stay the same. Dividends can be cut.

Learn: How to read a dividend

Full ABT quote · Forecast · Academy

Questions

When did ABT last raise the dividend?

Up from $0.59 to $0.63 on 15 January 2026.

How often does ABT pay a dividend?

4 Abbott Laboratories dividends were paid in the past year.

How many years has ABT raised the dividend?

In 5 of the last 5 years. 2025 totalled $2.36 a share.

What is the ABT dividend yield?

The Abbott Laboratories yield is 2.41%.

Abbott Laboratories (ABT) Dividend Yield & History

ABT price $104.71 -2.74 -2.55%

Ticker
ABT
Price
$104.71
Change
-2.74 -2.55%
Market cap
$181.35B
P/E
38.68
Forward P/E
18.00
Dividend yield
2.18%
Beta
0.54
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
45
Value
44
Quality
52
Growth
39

Stocklytics score rationale: value 44, quality 52, growth 39.

AI Score 75. Abbott Laboratories has a solid market capitalization of approximately $199.9 billion and a stable beta of 0.54, indicating lower volatility. However, its high price-to-earnings ratio of 42.8 and a negative price-to-earnings growth ratio suggest that the stock may be overvalued relative to its earnings growth potential

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener